Neoleukin Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Donna M. Cochener-Metcalfe
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 188 East Blaine Street Seattle WA United States of America 98102
- IPO Date
- Mar 7, 2014
- CIK
- 0001404644
- Website
- neoleukin.com
- Similar Companies
- Business
- Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) is a clinical-stage biopharmaceutical company that develops de novo protein therapeutics designed to improve patient outcomes in cancer and autoimmune diseases. The company engineers novel proteins using its proprietary de novo protein design technology platform, which enables the creation of protein therapeutics with predefined properties such as improved selectivity, potency, and reduced immunogenicity compared to traditional biologics. Its lead product candidate, NL-201, is a targeted IL-2/immunoglobulin complex agonist designed to preferentially activate and expand anti-tumor CD8 T cells and NK cells while minimizing activity on immunosuppressive regulatory T cells; additional pipeline candidates include NL-C101, a de novo CTLA-4 antagonist for immune checkpoint inhibition, and earlier-stage programs targeting autoimmune disorders like atopic dermatitis and inflammatory bowel disease. Neoleukin operates primarily in the United States, with preclinical and clinical activities focused on oncology and immunology segments serving pharmaceutical and biotechnology partners globally. Founded in 2019 and headquartered in Seattle, Washington, the company was spun out from the University of Washington protein design laboratory led by Nobel laureate David Baker. In recent developments, Neoleukin announced the appointment of Jonathan Zalevsky, Ph.D., as president and CEO in early 2024, marking a leadership transition to advance its clinical pipeline amid a strategic focus on monotherapy and combination therapy data readouts for NL-201 in advanced solid tumors.
Neoleukin Therapeutics (NASDAQ:NLTX) & Zymeworks (NASDAQ:ZYME) Critical Contrast
Reviewing Intellipharmaceutics International (OTCMKTS:IPCIF) & Neoleukin Therapeutics (NASDAQ:NLTX)
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
Redmile Group, LLC Boosts Stake in Neoleukin Therapeutics Inc
NEOLEUKIN THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX
Shareholder Alert: Ademi LLP investigates whether Neoleukin Therapeutics, Inc. has obtained a Fair Price in its Private Placement and its transaction with Neurogene
NLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to Shareholders
Neurogene and Neoleukin Announce Definitive Merger Agreement
Neoleukin Therapeutics: Strategic Review Play
Neoleukin (NLTX) Up 36% on Initiating Another Restructuring Plan
Shares of Neoleukin Therapeutics spike after announcing layoffs and potential sale or merger
Neoleukin (NLTX) Stops Development of Lead Drug, Stock Down
Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q2 2022 Results - Earnings Call Transcript
Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022
Neoleukin Therapeutics to Present at Upcoming Investor Conferences
Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference
Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q4 2021 Results - Earnings Call Transcript
Neoleukin Therapeutics Presenting at H.C. Wainwright BIOCONNECT Virtual Conference
Neoleukin Therapeutics to Present at Upcoming Investor Conferences